TrialLeukemia & lymphoma2016

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.

Clemens M Wendtner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.